Also the cancer drugs like PARP inhibitors seem to be helping everyone regardless of mutation status in clinical trials. So the connection is much less clear.
What I was saying was that those drugs have been proving effective regardless of mutation status. So mutation x = give drug Y connection is not really well understood.
Example, olaprib for Prostate cancer
> the addition of olaparib was associated with a significantly prolonged radiographic PFS irrespective of HRR status
https://www.practiceupdate.com/content/asco-gu-2022-propel-s...
I don't believe this is the case in general. Indeed, all cancer drugs fail sometimes, and there has to be something different about the cancers they fail on. If not the mutation status, then what?
Even FDA is approving these mutation targeting drugs without mutation status. Niraparib was approved for Ovarian Cancer even if you don't have HRD mutations. Approval was based on NOVA trial, you can lookup the details.
I am not saying there isn't any connection, what I am saying is it not really well understood or clearcut as mutation x = drug y that general public believes about these drugs.
Just because doctors do not know what to do with it (they are decades behind most research) it does not mean you cannot learn about this and take action on your own.
Just knowing my FADS1, FADS2 genetics was enough to change my diet to seafood only and raise my HDL from a consistent 35 to over 55 in three weeks. Doctors put me on a statin which lowered my HDL to 25.
Seafood helps everyone with HDL. Is 35 -> 55 not possible with those genes that you mentioned ?
We’re starting to get some good utility from sequencing. Currently whole exome is more informative than whole genome. But, there are definitely some good clinical uses!
https://rarediseases.info.nih.gov/diseases/9146/cardiofacioc...